Skip to main content

Table 4 Univariate logistic regression analysis of factors associated with the development of any grade ≥ 3 hematologic toxicity

From: Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy

Parameter

Odds ratio

95% CI

P value

Age (years)

1.000

0.972–1.029

0.991

BMI (kg/m2)

0.982

0.898–1.074

0.982

Duration of EBRT (days)

1.069

0.987–1.158

0.102

Clinical stage (FIGO2018)

1.759

0.964–3.208

0.066

Histology

0.559

0.232–1.345

0.194

Differentiation degree

0.789

0.431–1.445

0.443

PTV dose-pelvis

1.696

0.930–3.094

0.085

Cycles of chemotherapy

1.056

0.861–1.295

0.600

Volume (cm3)

1.002

1.000–1.004

0.053

Chemotherapy regimen

 TP

  

0.027*

 Carboplatin

0.257

0.094–0.701

0.008*

 Cisplatin

0.442

0.198–0.987

0.046*

TPB_V10

1.197

1.109–1.292

 < 0.001*

TPB_V20

1.176

1.109–1.248

 < 0.001*

TPB_V30

1.102

1.057–1.149

 < 0.001*

TPB_V40

1.114

1.055–1.177

 < 0.001*

TPB_V50

1.142

1.069–1.221

 < 0.001*

  1. BMI, body mass index; EBRT, pelvic external-beam radiotherapy; TPB_V10, TPB_V20, TPB_V30, TPB_V40, TPB_V50 = the total pelvic bones of volume receiving 10,20, 30, 40, 50 Gy; TP, paclitaxel + cisplatin. Bold indicates the significant values (*P < 0.05)